ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,507Medicare Part D Prescriptions Filled, Including Refills

Rank: 98 out of 2056

$514K Total Retail Price of All Prescriptions

Rank: 67 out of 2056

417 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
35% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Washington
Lower avg

Schedule Two
Controlled Substances

15% of this provider’s 417 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

14% of this provider’s 417 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

2% of this provider’s 5,997 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Washington
SIMVASTATIN 448 367 1 2
LISINOPRIL 320 234 2 1
LEVOTHYROXINE SODIUM 289 236 3 3
HYDROCODONE-ACETAMINOPHEN 281 144 S3 4 5
OMEPRAZOLE 235 202 5 4
AMLODIPINE BESYLATE 216 158 6 6
OXYCODONE HCL 202 106 S2 7 24
GABAPENTIN 177 81 8 14
WARFARIN SODIUM 158 135 9 12
CITALOPRAM HBR 145 118 10 15
ZOLPIDEM TARTRATE 137 111 11 23
METFORMIN HCL 124 81 12 8
METOPROLOL SUCCINATE 114 87 13 19
FUROSEMIDE 112 104 14 9
HYDROCHLOROTHIAZIDE 105 74 15 7
PRAVASTATIN SODIUM 101 70 16 20
MORPHINE SULFATE ER 97 25 S2 17 36
LOSARTAN POTASSIUM 95 95 18 13
RANITIDINE HCL 90 57 19 22
CRESTOR 85 74 20 30
ALENDRONATE SODIUM 81 66 21 26
ADVAIR DISKUS 81 48 21 51
FLUTICASONE PROPIONATE 80 56 23 31
SERTRALINE HCL 80 70 23 25
DONEPEZIL HCL 74 74 25 37
METOPROLOL TARTRATE 74 66 25 11
TRAZODONE HCL 72 52 27 21
QUETIAPINE FUMARATE 71 47 28 61
TAMSULOSIN HCL 68 55 29 28
ATENOLOL 67 62 30 10
PROAIR HFA 64 48 31 29
SPIRIVA 57 53 32 42
CYCLOBENZAPRINE HCL 57 22 R 32 52
BUSPIRONE HCL 56 56 34 102
LOVASTATIN 55 37 35 16
ATORVASTATIN CALCIUM 54 43 36 17
GLIMEPIRIDE 54 35 36 67
RISPERIDONE 53 25 38 48
AZITHROMYCIN 53 37 38 54
NIASPAN 52 32 40 126
NAMENDA 51 51 41 62
NORTRIPTYLINE HCL 50 27 42 100
ALLOPURINOL 50 38 42 32
TIZANIDINE HCL 50 0 42 132
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 16, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.